Trial · NCT07906678
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Muscle mass | Baseline assessment on November 15, 2026, before initiation of the intervention, and post-intervention assessment on January 10, 2027, after completion of the 8-week intervention. | Muscle mass will be assessed at baseline and immediately after completion of the 8-week intervention using a calibrated TANITA SC-240 bioelectrical impedance analyzer. Change in muscle mass will be calculated for each participant by subtracting baseline muscle mass from Week 8 muscle mass. The change will be compared between the magnesium complex and placebo groups to evaluate the effect of daily magnesium complex supplementation on muscle mass in healthy young adults. Muscle mass will be expressed in kilograms (kg). |
| Primary | Body composition | Baseline assessment on November 15, 2026, before initiation of the intervention, and post-intervention assessment on January 10, 2027, after completion of the 8-week intervention. | Body fat percentage will be assessed at baseline and immediately after completion of the 8-week intervention using a calibrated TANITA SC-240 bioelectrical impedance analyzer. Change in body fat percentage will be calculated for each participant by subtracting the baseline body fat percentage from the Week 8 body fat percentage. The change will be compared between the magnesium complex and placebo groups to evaluate the effect of daily magnesium complex supplementation on body fat percentage in healthy young adults. Body fat percentage will be expressed as a percentage (%). |
| Secondary | Body weight | Baseline assessment on November 15, 2026, before initiation of the intervention, and post-intervention assessment on January 10, 2027, after completion of the 8-week intervention. | Body weight will be measured at baseline and immediately after completion of the 8-week intervention using standardized procedures. Change in body weight will be calculated for each participant by subtracting baseline body weight from body weight at Week 8. The change will be compared between the magnesium complex and placebo groups. Body weight will be expressed in kilograms (kg). |
| Secondary | Height | Baseline assessment on November 15, 2026, before initiation of the intervention, and post-intervention assessment on January 10, 2027, after completion of the 8-week intervention. | Height will be measured at baseline and immediately after completion of the 8-week intervention using standardized procedures. Change in height will be calculated by subtracting baseline height from height at Week 8. Height will be expressed in centimeters (cm). |
| Secondary | Body mass index (BMI) | Baseline assessment on November 15, 2026, before initiation of the intervention, and post-intervention assessment on January 10, 2027, after completion of the 8-week intervention. | Body mass index (BMI) will be assessed at baseline and immediately after completion of the 8-week intervention. BMI will be calculated by dividing body weight in kilograms by height in meters squared (kg/m²). Change in BMI will be calculated for each participant by subtracting baseline BMI from BMI at Week 8. The change will be compared between the magnesium complex and placebo groups. BMI will be expressed in kilograms per square meter (kg/m²). |
| Secondary | Waist circumference | Baseline assessment on November 15, 2026, before initiation of the intervention, and post-intervention assessment on January 10, 2027, after completion of the 8-week intervention. | Waist circumference will be measured at baseline and immediately after completion of the 8-week intervention using standardized procedures. Change in waist circumference will be calculated by subtracting baseline waist circumference from waist circumference at Week 8. The change will be compared between the magnesium complex and placebo groups. Waist circumference will be expressed in centimeters (cm). |
| Secondary | Hip circumference | Baseline assessment on November 15, 2026, before initiation of the intervention, and post-intervention assessment on January 10, 2027, after completion of the 8-week intervention. | Hip circumference will be measured at baseline and immediately after completion of the 8-week intervention using standardized procedures. Change in hip circumference will be calculated by subtracting baseline hip circumference from hip circumference at Week 8. The change will be compared between the magnesium complex and placebo groups. Hip circumference will be expressed in centimeters (cm). |
| Secondary | Waist-to-hip ratio | Baseline assessment on November 15, 2026, before initiation of the intervention, and post-intervention assessment on January 10, 2027, after completion of the 8-week intervention. | Waist-to-hip ratio will be calculated at baseline and immediately after completion of the 8-week intervention by dividing waist circumference by hip circumference. Change in waist-to-hip ratio will be calculated by subtracting the baseline ratio from the Week 8 ratio. The change will be compared between the magnesium complex and placebo groups. Waist-to-hip ratio is dimensionless and has no unit of measurement. |
| Secondary | Serum magnesium concentration | Baseline assessment on November 15, 2026, before initiation of the intervention, and post-intervention assessment on January 10, 2027, after completion of the 8-week intervention. | Serum magnesium concentration will be assessed at baseline and immediately after completion of the 8-week intervention. The change in serum magnesium concentration will be calculated for each participant by subtracting the baseline concentration from the Week 8 concentration. Changes will be compared between the magnesium complex and placebo groups to evaluate the effect of supplementation on serum magnesium levels. Serum magnesium concentration will be expressed in mg/dL. |
| Other | Age | At baseline (before randomization). | Age will be recorded in completed years at baseline and treated as a continuous covariate in the statistical analysis. |
| Other | Sex | At baseline (before randomization). | Sex will be recorded at baseline according to participants' reported information and included as a covariate in the statistical analysis. |
| Other | Sunlight exposure | Baseline assessment on November 15, 2026, before initiation of the intervention, and post-intervention assessment on January 10, 2027, after completion of the 8-week intervention. | Sunlight exposure will be assessed at baseline and Week 8 using participants' reported duration of exposure and time of day. Exposure duration will be recorded in minutes or hours per day, and time of day will be categorized according to the study's predefined categories. Changes during the intervention will be assessed where applicable. |
| Other | Physical activity level | Baseline assessment on November 15, 2026, before initiation of the intervention, and post-intervention assessment on January 10, 2027, after completion of the 8-week intervention. | Physical activity level will be assessed using the International Physical Activity Questionnaire-Short Form (IPAQ-SF) at baseline and immediately after the 8-week intervention. Physical activity will be quantified as metabolic equivalent task minutes per week (MET-min/week), based on reported walking, moderate-intensity, and vigorous-intensity activities. The total score ranges from 0 MET-min/week to no fixed upper limit. Higher scores indicate greater physical activity. Physical activity may also be categorized as low, moderate, or high according to the standard IPAQ-SF scoring protocol. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07906678/registered